Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment.
about
Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy.Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research.Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma.Assessment of pharmacokinetic interaction between rilotumumab and epirubicin, cisplatin and capecitabine (ECX) in a Phase 3 study in gastric cancer.89Zr-DFO-AMG102 Immuno-PET to Determine Local Hepatocyte Growth Factor Protein Levels in Tumors for Enhanced Patient Selection.A Phase 1/1b tolerability study of rilotumumab alone or in combination with cisplatin and capecitabine in Japanese patients with gastric cancer.
P2860
Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment.
@en
Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment.
@nl
type
label
Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment.
@en
Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment.
@nl
prefLabel
Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment.
@en
Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment.
@nl
P2093
P2860
P1433
P1476
Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment.
@en
P2093
Rajul K Jain
Yilong Zhang
P2860
P304
P356
10.3390/BIOMEDICINES3010149
P577
2015-03-19T00:00:00Z